Literature DB >> 22411231

Age-related macular degeneration.

Sam Khandhadia1, Jocelyn Cherry, Andrew John Lotery.   

Abstract

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. Despite recent advances in treatment, AMD causes considerable morbidity. For the non-ophthalmologist, a brief background on retinal structure is provided, followed by a description of the characteristic changes seen in AMD. Subsequently the typical clinical features of AMD are discussed with an outline of present management, followed by the current theories of AMD pathogenesis. The similarities between AMD and another neurodegenerative disease are then highlighted. Finally, we review the on-going clinical trials of potential treatments for the future. Since it is clear that multiple risk factors are involved in the pathogenesis of AMD, a multi-faceted approach will most likely be required in order to prevent further patients progressing to blindness as a result of this devastating condition.

Entities:  

Mesh:

Year:  2012        PMID: 22411231     DOI: 10.1007/978-1-4614-0653-2_2

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  32 in total

1.  Rapid and efficient directed differentiation of human pluripotent stem cells into retinal pigmented epithelium.

Authors:  David E Buchholz; Britney O Pennington; Roxanne H Croze; Cassidy R Hinman; Peter J Coffey; Dennis O Clegg
Journal:  Stem Cells Transl Med       Date:  2013-04-18       Impact factor: 6.940

2.  Defined culture of human embryonic stem cells and xeno-free derivation of retinal pigmented epithelial cells on a novel, synthetic substrate.

Authors:  Britney O Pennington; Dennis O Clegg; Zara K Melkoumian; Sherry T Hikita
Journal:  Stem Cells Transl Med       Date:  2015-01-15       Impact factor: 6.940

3.  Restoring visual function to blind mice with a photoswitch that exploits electrophysiological remodeling of retinal ganglion cells.

Authors:  Ivan Tochitsky; Aleksandra Polosukhina; Vadim E Degtyar; Nicholas Gallerani; Caleb M Smith; Aaron Friedman; Russell N Van Gelder; Dirk Trauner; Daniela Kaufer; Richard H Kramer
Journal:  Neuron       Date:  2014-02-19       Impact factor: 17.173

4.  Digital reader vs print media: the role of digital technology in reading accuracy in age-related macular degeneration.

Authors:  K Gill; A Mao; A M Powell; T Sheidow
Journal:  Eye (Lond)       Date:  2013-03-15       Impact factor: 3.775

5.  A simple and scalable process for the differentiation of retinal pigment epithelium from human pluripotent stem cells.

Authors:  Julien Maruotti; Karl Wahlin; David Gorrell; Imran Bhutto; Gerard Lutty; Donald J Zack
Journal:  Stem Cells Transl Med       Date:  2013-04-12       Impact factor: 6.940

Review 6.  Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration.

Authors:  James E Frampton
Journal:  Drugs Aging       Date:  2013-05       Impact factor: 3.923

7.  Visual function assessment in simulated real-life situations in patients with age-related macular degeneration compared to normal subjects.

Authors:  G Barteselli; M L Gomez; A L Doede; J Chhablani; W Gutstein; D-U Bartsch; L Dustin; S P Azen; W R Freeman
Journal:  Eye (Lond)       Date:  2014-08-01       Impact factor: 3.775

8.  Complement regulatory protein CD46 protects against choroidal neovascularization in mice.

Authors:  Valeriy Lyzogubov; Xiaobo Wu; Purushottam Jha; Ruslana Tytarenko; Michael Triebwasser; Grant Kolar; Paula Bertram; Puran S Bora; John P Atkinson; Nalini S Bora
Journal:  Am J Pathol       Date:  2014-07-11       Impact factor: 4.307

9.  The Complement Regulatory Protein CD46 Deficient Mouse Spontaneously Develops Dry-Type Age-Related Macular Degeneration-Like Phenotype.

Authors:  Valeriy V Lyzogubov; Puran S Bora; Xiaobo Wu; Leah E Horn; Ryan de Roque; Xeniya V Rudolf; John P Atkinson; Nalini S Bora
Journal:  Am J Pathol       Date:  2016-06-11       Impact factor: 4.307

10.  Controlled release of photoswitch drugs by degradable polymer microspheres.

Authors:  Rebecca Groynom; Erin Shoffstall; Larry S Wu; Richard H Kramer; Erin B Lavik
Journal:  J Drug Target       Date:  2015       Impact factor: 5.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.